Bellerophon Therapeutics, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Bellerophon Therapeutics, Inc. reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $1.33 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2020-11-05
- Bellerophon Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2020-09-30 was $2.63M, a 1465.48% increase year-over-year.
- Bellerophon Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2020-06-30 was -$467.00K.
- Bellerophon Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2020-03-31 was -$830.00K.
- Bellerophon Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2019-09-30 was $168.00K, a 380.00% increase year-over-year.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month |
|---|---|---|---|
| 2020-09-30 | $2.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $2.16M derived: sum of 2 quarters · filed 2020-11-05 | $1.33M 10-Q · filed 2020-11-05 |
| 2020-06-30 | -$467.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$1.30M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | -$830.00K 10-Q · filed 2020-05-11 | ||
| 2019-09-30 | $168.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$260.00K derived: sum of 2 quarters · filed 2020-11-05 | -$987.00K 10-Q · filed 2020-11-05 |
| 2019-06-30 | -$428.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$1.16M 10-Q · filed 2020-08-05 | |
| 2019-03-31 | -$727.00K 10-Q · filed 2020-05-11 | ||
| 2018-09-30 | $35.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $678.00K derived: sum of 2 quarters · filed 2019-11-06 | $2.02M 10-Q · filed 2019-11-06 |
| 2018-06-30 | $643.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $1.99M 10-Q · filed 2019-08-08 | |
| 2018-03-31 | $1.34M 10-Q · filed 2019-05-09 | ||
| 2017-09-30 | $244.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$352.00K derived: sum of 2 quarters · filed 2018-11-07 | -$552.00K 10-Q · filed 2018-11-07 |
| 2017-06-30 | -$596.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | -$796.00K 10-Q · filed 2018-08-01 | |
| 2017-03-31 | -$200.00K 10-Q · filed 2018-05-10 | ||
| 2016-09-30 | -$1.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$3.30M 10-Q · filed 2017-11-07 | |
| 2016-06-30 | -$1.95M 10-Q · filed 2017-08-07 |